Recent Finacing
Recent Raise
Jasper Therapeutics develops JSP191, a humanized anti‑CD117 monoclonal antibody as a chemotherapy‑ and radiation‑sparing conditioning regimen for hematopoietic stem cell transplants and gene therapies, currently in Phase 1/2.
